ID: ALA121469

Max Phase: Preclinical

Molecular Formula: C20H17ClN2O4

Molecular Weight: 348.36

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cl.NCCCn1c2c(c3ccccc3c1=O)C(=O)c1cc3c(cc1-2)OCO3

Standard InChI:  InChI=1S/C20H16N2O4.ClH/c21-6-3-7-22-18-13-8-15-16(26-10-25-15)9-14(13)19(23)17(18)11-4-1-2-5-12(11)20(22)24;/h1-2,4-5,8-9H,3,6-7,10,21H2;1H

Standard InChI Key:  GXCGKOMCESZDHE-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 348.36

Molecular Weight (Monoisotopic): 348.1110

AlogP: 2.29

#Rotatable Bonds: 3

Polar Surface Area: 83.55

Molecular Species: BASE

HBA: 6

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 9.57

CX LogP: 1.00

CX LogD: -1.11

Aromatic Rings: 3

Heavy Atoms: 26

QED Weighted: 0.61

Np Likeness Score: 0.23

References

1. Morrell A, Antony S, Kohlhagen G, Pommier Y, Cushman M..  (2004)  Synthesis of nitrated indenoisoquinolines as topoisomerase I inhibitors.,  14  (14): [PMID:15203138] [10.1016/j.bmcl.2004.05.022]

2. Nagarajan M, Morrell A, Fort BC, Meckley MR, Antony S, Kohlhagen G, Pommier Y, Cushman M..  (2004)  Synthesis and anticancer activity of simplified indenoisoquinoline topoisomerase I inhibitors lacking substituents on the aromatic rings.,  47  (23): [PMID:15509164] [10.1021/jm040025z]

3. Morrell A, Jayaraman M, Nagarajan M, Fox BM, Meckley MR, Ioanoviciu A, Pommier Y, Antony S, Hollingshead M, Cushman M..  (2006)  Evaluation of indenoisoquinoline topoisomerase I inhibitors using a hollow fiber assay.,  16  (16): [PMID:16750365] [10.1016/j.bmcl.2006.05.048]

Source

Source(1):

• Scientific Literature